Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept versus 5-fluorouracil as subconjunctival adjuvant therapy after pterygium surgery
ChiCTR-IPR-17012546Phase 4Recruiting
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Sep 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of conbercept in pterygium (2 arms), sponsored by Zhongnan Hospital of Wuhan University. Primary endpoints: Pterygium morphology, Color intensity and 1 more. Started Sep 2017; status: recruiting.
02
Drugs
conbercept
03
Conditions
pterygium
Beyond the preview
Go deeper on ChiCTR-IPR-17012546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012546.